Roche stock gains as Genentech lands a $190 million deal

Roche stock gained 0.6% to CHF 372.50 on August 25, 2026, while Genentech signed a $190 million obesity licensing deal and the shares touched CHF 375.60 this month.

Roche Holding AG (CH0012032048) stock closed at CHF 372.50 in SIX SX trading at 4:28 p.m. on August 25, 2026, up 0.6%, while the shares reached CHF 375.60 on August 21, 2026 and traded with 175,180 shares of volume that session.

A separate market note put Roche's market capitalization at $368.49 billion and flagged the stock as 39.9% above a GF Value estimate, with the same note highlighting a 2.68% dividend yield and a 55% payout ratio. The stock also changed hands at CHF 371.00 at the open on August 25, 2026, giving investors a tight intraday range to watch.

Genentech adds a pipeline option

GuruFocus reported on August 25, 2026 that Genentech finalized a licensing agreement with Hanmi Pharmaceutical for the obesity candidate HM17321, with $190 million upfront and potential milestone and royalty payments that could reach $2.3 billion. That makes the deal a concrete pipeline lever rather than a broad strategic statement.

The same report said Roche's oncology products account for 40% of pharmaceutical sales, which helps explain why the group still gets valued as a dual franchise in oncology and diagnostics. A 40% contribution from one pharmaceutical area also shows how much the new metabolic push has to sit beside a very large existing base.

Price still matters

On August 25, 2026, the shares were 32.30% above the 52-week low of CHF 252.20 and only 0.83% below the 52-week high of CHF 375.60. That leaves the recent move close to a chart ceiling even after the latest gain.

Experts in the same market note set 2026 earnings per Roche share at CHF 20.26 and pointed to a next results date of February 4, 2027. Those figures frame the stock's valuation debate as the market weighs pipeline news against a high base level.

HM17321 focus

HM17321 is designed as an obesity drug candidate, and the reported deal gives Roche global manufacturing and marketing rights outside South Korea after development moves from phase 1 to phase 2. For Roche, that adds another external asset to a portfolio that still leans heavily on cancer and diagnostics.

Roche stock at a glance

Roche stock ended August 25, 2026 at CHF 372.50 in SIX SX trading.

As of August 25, 2026, the stock's 52-week range ran from CHF 252.20 to CHF 375.60, and the market value cited in the market note stood at $368.49 billion.

Company

Company: Roche Holding AG

ISIN: CH0012032048

Ticker: ROG

Exchange: SIX Swiss Exchange

Sector / Industry: Healthcare / Pharmaceuticals

Index membership: Swiss Market Index

Next earnings date: February 4, 2027

Media_Description

Roche stock with Genentech deal and price data

Media_Alt

Roche stock and Genentech pipeline deal